SITC is pleased to announce the publication of the lung cancer and mesothelioma clinical practice guideline (CPG). The recommendations in this guideline will provide a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers on topics including biomarkers; the selection of appropriate immunotherapeutic regimens for NSCLC, SCLC and mesothelioma; treatment response and monitoring; and patient quality of life considerations. The manuscript, the latest in the ongoing series of SITC Cancer Immunotherapy Guidelines, is available now in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal.
SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
SITC is pleased to offer free webinars featuring Expert Panel members from SITC's Lung Cancer and Mesothelioma Immunotherapy Guideline. These educational offerings are designed for healthcare providers who treat cancer patients including oncologists, physicians, disease specialists, registered nurses, nurse practitioners, pharmacists and physician assistants. The live webinars include a dedicated question-and-answer session providing the opportunity for attendees to converse with the faculty and ask questions about the guideline recommendations.
Charu Aggarwal, MD, MPH — University of Pennsylvania
Scott J. Antonia, MD, PhD — Duke University School of Medicine
Marianne Davies, DNP, AOCNP — Yale School of Nursing
Steven M. Dubinett, MD — David Geffen School of Medicine at UCLA
Andrea Ferris, MBA — LUNGevity
Patrick Forde, MD — Johns Hopkins University School of Medicine
Edward B. Garon, MD — University of California, Los Angeles
Sarah B. Goldberg, MD, MPH — Yale School of Medicine, Yale Cancer Center
Raffit Hassan, MD — National Institutes of Health
Matthew D. Hellmann, MD — Memorial Sloan Kettering Cancer Center
Fred R. Hirsch, MD, PhD — Icahn School of Medicine at Mount Sinai
Melissa L. Johnson, MD — Sarah Cannon Research Institute
Shakuntala Malik, MD — National Cancer Institute
Daniel Morgensztern, MD — Siteman Cancer Center, Washington University School of Medicine
Joel Neal, MD, PhD — Stanford University
Jyoti Patel, MD — Robert H. Lurie Comprehensive Cancer Center of Northwestern University
David L. Rimm, MD, PhD — Yale University
Sarah Sagorsky, PA-C — Johns Hopkins University School of Medicine
Lawrence H. Schwartz, MD — Columbia University Medical Center
Boris Sepesi, MD, FACS — The University of Texas MD Anderson Cancer Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org